FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/4f6Ew5KGmg https://t.co/SldJ6MXMw7 https://t.co/KfCww7doef
Links:
FDA approves Novartis Cosentyx® as the first new biologic treatment option for …
https://bit.ly/3Squ4GQ
05-11-2023
